Total Payments
$330,585
2024 Payments
$49,876
Companies
39
Transactions
334
Medicare Patients
79
Medicare Billing
$26,827
Payment Breakdown by Category
Consulting$176,201 (53.3%)
Research$59,062 (17.9%)
Travel$57,694 (17.5%)
Other$30,467 (9.2%)
Food & Beverage$7,035 (2.1%)
Education$125.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $176,201 | 71 | 53.3% |
| Unspecified | $59,062 | 39 | 17.9% |
| Travel and Lodging | $57,694 | 70 | 17.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,467 | 49 | 9.2% |
| Food and Beverage | $7,035 | 101 | 2.1% |
| Education | $125.61 | 4 | 0.0% |
Payments by Type
General
$271,523
295 transactions
Research
$59,062
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim International GmbH | $46,109 | 56 | $0 (2024) |
| F. Hoffmann-La Roche AG | $30,848 | 19 | $0 (2022) |
| PFIZER INC. | $27,549 | 31 | $0 (2024) |
| ABBVIE INC. | $25,673 | 40 | $0 (2024) |
| Amgen Inc. | $21,300 | 18 | $0 (2024) |
| EMD Serono, Inc. | $18,747 | 15 | $0 (2020) |
| Ipsen Biopharmaceuticals, Inc | $16,861 | 16 | $0 (2020) |
| Halozyme Inc | $16,208 | 8 | $0 (2019) |
| Genentech USA, Inc. | $15,036 | 22 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $12,281 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,876 | 53 | Amgen Inc. ($11,675) |
| 2023 | $48,348 | 42 | Boehringer Ingelheim International GmbH ($23,426) |
| 2022 | $28,841 | 22 | F. Hoffmann-La Roche AG ($17,821) |
| 2021 | $19,350 | 17 | Boehringer Ingelheim International GmbH ($7,137) |
| 2020 | $37,472 | 19 | Ipsen Biopharmaceuticals, Inc ($9,240) |
| 2019 | $44,576 | 53 | PFIZER INC. ($10,493) |
| 2018 | $42,921 | 53 | AbbVie, Inc. ($16,193) |
| 2017 | $59,202 | 75 | F. Hoffmann-La Roche AG ($11,246) |
All Payment Transactions
334 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
| 10/29/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $2,062.50 | General |
| 10/29/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 10/29/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,050.00 | General |
| 10/23/2024 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $694.52 | Research |
| Study: A PHASE 1 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | ||||||
| 10/22/2024 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,649.50 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $1,512.50 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 10/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 10/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,075.00 | General |
| 10/22/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,075.00 | General |
| 09/12/2024 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $37.35 | Research |
| Study: A PHASE 1 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | ||||||
| 09/12/2024 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $12.11 | Research |
| Study: A PHASE 1 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | ||||||
| 09/03/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $40.36 | General |
| 09/03/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $16.36 | General |
| 09/03/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $16.36 | General |
| 09/02/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Travel and Lodging | In-kind items and services | $6,550.04 | General |
| 09/02/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Travel and Lodging | In-kind items and services | $525.82 | General |
| 09/02/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $54.54 | General |
| 09/02/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $40.36 | General |
| 09/02/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $16.36 | General |
| 09/02/2024 | Boehringer Ingelheim Pharma GmbH & Co.KG | — | Food and Beverage | In-kind items and services | $16.36 | General |
| 08/15/2024 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| 08/15/2024 | Kyowa Kirin, Inc. | — | Travel and Lodging | Cash or cash equivalent | $41.92 | General |
| 07/09/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,800.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $8,442 | 2 |
| SHATTUCK: SL-115154 (CSF1R-FC-CD40L) | Takeda Pharmaceuticals U.S.A., Inc. | $6,645 | 4 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects Wit | Halozyme Inc | $5,874 | 1 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant | Halozyme Inc | $5,000 | 2 |
| A PHASE 1A/1B STUDY OF LY3405105 ADMINISTERED TO PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $4,849 | 2 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma | Halozyme Inc | $4,560 | 2 |
| COFETUZUMAB PELIDOTIN CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 2 |
| AZA-ST-001 - A Phase 1 Study of CC-486 as a Single Agent and in Combination with Carboplatin or ABI-007 in Subjects with Relapsed or Refractory Solid Tumors | Celgene Corporation | $3,444 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE AND MULTIPLE DOSES OF TAK-861 IN HEALTHY ADULT AND ELDERLY SUBJECTS AND SUBJECTS WITH NARCOLEPSY TYPE 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,450 | 1 |
| NEW PROTOCOL TO BE ADDED | Takeda Pharmaceuticals U.S.A., Inc. | $2,100 | 1 |
| PF06804103 MAVELERTINIB PF4136309 PF06952229 NIROGACESTAT PF06671008 ARRY 382 PF04691502 PF06821497 PF06939999 PF06840003 PF07265807 COFETUZUMAB PELIDOTIN MULTI PRODUCT UTOMILUMAB GEDATOLISIB ELRANATAMAB PF067535 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,880 | 2 |
| CC-90003-ST-001 | Celgene Corporation | $1,488 | 1 |
| PALBOCICLIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
| TAK-280-1501 | Takeda Pharmaceuticals U.S.A., Inc. | $1,050 | 1 |
| A PHASE 1 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMAC | GlaxoSmithKline, LLC. | $743.98 | 3 |
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $660.00 | 2 |
| A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | SANOFI US SERVICES INC. | $375.10 | 1 |
| GEDATOLISIB PF06840003 PF04691502 PF06939999 PF06650808 ELRANATAMAB PF06952229 PF06821497 PF07265807 PF06804103 TRASTUZUMAB PFIZER PF06664178 PF06940434 NIROGACESTAT PF06671008 TINLORAFENIB PF06753512 MAVELERTI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| PF06647263 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma | GENZYME CORPORATION | $242.71 | 1 |
| A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | AbbVie Inc. | $50.87 | 1 |
| M16-074 | AbbVie, Inc. | $36.28 | 1 |
| A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors | ABBVIE INC. | $25.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 43 | 89 | $41,415 | $9,457 |
| 2022 | 1 | 19 | 79 | $39,105 | $9,775 |
| 2021 | 1 | 17 | 61 | $30,195 | $7,596 |
Total Patients
79
Total Services
229
Medicare Billing
$26,827
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 29 | 67 | $33,165 | $7,727 | 23.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 14 | 22 | $8,250 | $1,730 | 21.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 19 | 79 | $39,105 | $9,775 | 25.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 17 | 61 | $30,195 | $7,596 | 25.2% |
About Dr. Patricia Lorusso, DO
Dr. Patricia Lorusso, DO is a Internal Medicine healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932146420.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patricia Lorusso, DO has received a total of $330,585 in payments from pharmaceutical and medical device companies, with $49,876 received in 2024. These payments were reported across 334 transactions from 39 companies. The most common payment nature is "Consulting Fee" ($176,201).
As a Medicare-enrolled provider, Lorusso has provided services to 79 Medicare beneficiaries, totaling 229 services with total Medicare billing of $26,827. Data is available for 3 years (2021–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Detroit, MI
- Active Since 06/01/2006
- Last Updated 11/01/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1932146420
Products in Payments
- Non-Covered Product (Drug) $16,255
- Herceptin (Biological) $9,865
- LYNPARZA (Drug) $7,630
- Onivyde (Drug) $7,621
- TAFINLAR (Drug) $7,186
- ELZONRIS (Drug) $5,440
- TECENTRIQ (Biological) $5,092
- LUMAKRAS (Drug) $5,087
- SOMATULINE DEPOT (Drug) $3,850
- CC-486 (Drug) $3,444
- Cenobamate (Drug) $3,238
- ELREXFIO (Drug) $2,870
- Kadcyla (Biological) $2,556
- XCOPRI (Drug) $2,100
- TUKYSA (Drug) $1,650
- BINIMETINIB (Drug) $1,257
- ZEPZELCA (Drug) $1,000
- SAR245409 (Drug) $617.81
- IMFINZI (Biological) $342.50
- IMFINZI (Drug) $185.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Detroit
Randy Lieberman, Md, MD
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Dr. Philip Philip, Md Phd Frcp, MD PHD FRCP
Internal Medicine — Payments: $708,561
Internal Medicine $708,561
Shirish Gadgeel, Md, MD
Internal Medicine — Payments: $563,542
Internal Medicine $563,542
Pedro Villablanca Spinetto, M.d, M.D
Internal Medicine — Payments: $480,267
Internal Medicine $480,267
Dr. Mir Basir, D.o, D.O
Internal Medicine — Payments: $415,569
Internal Medicine $415,569
Dr. Ammar Sukari, M.d, M.D
Internal Medicine — Payments: $371,746
Internal Medicine $371,746